Caregiver Dose After Radiopharmaceutical Therapy

When a patient is released after I-131 or Lu-177 therapy, the radiation source walks out the door with them. The people who then share a home, a car, and a bed with that patient — spouses, parents, children, caregivers — can receive a real, if usually small, radiation dose. A defensible therapy program does not leave that to chance. It applies the right release criterion, hands the patient the right written instructions, and grounds the whole thing in the dose constraints that regulators and international bodies have set for family, caregivers, and the public.¹³⁴

Introduction

Radiopharmaceutical therapy has grown from a handful of radioiodine treatments into a broad and expanding field — I-131 for thyroid disease and thyroid cancer, Lu-177 for neuroendocrine tumors and prostate cancer, and others. In almost every case, the patient is treated and then goes home while still containing radioactive material. That is by design: hospitalizing every therapy patient carries significant psychological, monetary, and logistical burdens, and the U.S. framework deliberately allows outpatient release when the projected dose to others is acceptable.¹⁴

But "goes home" means the source term goes into an uncontrolled environment full of people who never consented to be radiation workers. External exposure to a spouse sleeping beside the patient, contamination risk to a small child from saliva, dose to a nursing infant through breast milk, exposure to a caregiver helping with daily activities — these are the pathways a radiation safety program must anticipate before the patient leaves the department.⁴

The regulatory and scientific structure for managing this is well established. The Nuclear Regulatory Commission (NRC) sets the release criterion and the instruction requirement in 10 CFR 35.75; NRC Regulatory Guide 8.39 provides the methodology; and NCRP Report No. 155 and ICRP Publication 94 supply the dose-constraint framework that distinguishes a knowing adult caregiver from a young child or a casual visitor.¹²³⁴ This article walks through those pieces, works a dose estimate, and translates it into the practical instructions and program controls that keep household doses as low as reasonably achievable. DRPS supports this work through radioactive material license support and radiation safety officer consulting across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The release criterion: 5 mSv to any other individual

The governing rule is 10 CFR 35.75. A licensee may release a patient who has been administered unsealed byproduct material if the total effective dose equivalent (TEDE) to any other individual from exposure to the released patient is not likely to exceed 5 mSv (0.5 rem).¹ The criterion is written around the most exposed other person — typically the household member in closest, longest contact — and it is a per-treatment projection, not an annual accumulation.

The release decision can be based on the administered activity, on the measured dose rate from the patient, or on a patient-specific calculation that accounts for factors such as biological clearance and living situation. NRC Regulatory Guide 8.39, whose current Revision 1 was issued in 2020, provides the activity thresholds, dose-rate thresholds, and default occupancy assumptions that support each approach.² For example, for I-131 the guide identifies an activity-based release threshold of 1.2 GBq (33 mCi) and a dose-rate-based threshold of 0.07 mSv/h (7 mrem/h) at 1 meter; a patient at or below those values can generally be released under the 5 mSv criterion, while higher activities require a patient-specific evaluation.²

This release ecosystem connects directly to our companion guide on patient release after radiopharmaceutical therapy; the present article focuses on the people the released patient goes home to.

The instruction trigger: 1 mSv

Release is only half the obligation. Under 10 CFR 35.75(b), when the TEDE to any other individual is likely to exceed 1 mSv (0.1 rem), the licensee must give the patient — or the patient's parent or guardian — instructions, including written instructions, on how to keep exposure to others as low as reasonably achievable.¹ And if a nursing infant or child could receive more than 1 mSv assuming breastfeeding continued uninterrupted, the instructions must address interrupting or discontinuing breastfeeding.¹ For radioiodine specifically, breastfeeding must cease.⁴ The 1 mSv figure is therefore not just a number; it is the switch that turns a release into a release-plus-instructions.

Key Technical Principles

Who gets which constraint

Not everyone in the patient's life is held to the same standard. The framework deliberately separates the knowing adult who chooses to help from the child who cannot.

Group / scenario	Governing framework	Dose figure
Any other individual (release criterion)	10 CFR 35.75(a)	≤ 5 mSv TEDE per release ¹
Trigger for required written ALARA instructions	10 CFR 35.75(b)	likely > 1 mSv TEDE ¹
Adult relatives, caregivers, and comforters helping knowingly and voluntarily	ICRP Publication 94 (optimization constraint)	a few mSv per episode (constraint, not limit) ⁴
Young children, infants, and visitors not providing direct care	ICRP Publication 94; public dose limit	1 mSv (public limit) ⁴⁵
Visitors to a patient who cannot be released (hospitalized)	10 CFR 20.1301(c)	> 1 mSv permitted, up to 5 mSv, with authorized-user approval ⁵
Nursing infant (breastfeeding)	10 CFR 35.75(b)	instructions if could exceed 1 mSv; radioiodine requires cessation ¹⁴

The key distinction comes from ICRP Publication 94: the ICRP recommends "a source-related dose constraint for optimisation of a few mSv/episode" for relatives, visitors, and caregivers at home, rather than a dose limit, in recognition that these people are knowingly and voluntarily helping a patient they care about. But the same report is explicit that "young children and infants, as well as visitors not engaged in direct care or comforting, should be treated as members of the public" — that is, subject to the 1 mSv public dose limit.⁴ The public dose limit itself is set in 10 CFR 20.1301, which caps public dose at 1 mSv (0.1 rem) per year while explicitly excluding dose from patients released under 35.75.⁵

Estimating dose to a household member

The dose another person receives from a released patient is estimated by treating the patient as a decaying point source. For a dose rate $\dot{D}_{1}$ measured at a reference distance of 1 meter at the time of release, a person spending a fraction of time (occupancy factor $E$ ) at an average distance $d$ from the patient, the cumulative dose integrated over the radionuclide's decay is:

D = \frac{D ˙ _{1}}{d ^{2}} \cdot E \cdot \int_{0}^{\infty} e^{- λ t} d t = \frac{D ˙ _{1}}{d ^{2}} \cdot E \cdot 1.44 T_{1/2}

where $λ$ is the decay constant, $T_{1/2}$ is the (effective) half-life, and the mean life $1/ λ = 1.44 T_{1/2}$ . The inverse-square factor $1/ d^{2}$ rewards distance, the occupancy factor rewards reduced time, and the integral captures the fact that the source is decaying away the whole time.²⁶

A worked example makes the levers visible. Consider an I-131 patient released with a measured dose rate of $\dot{D}_{1} = 0.05 mSv/h$ at 1 meter — below the 0.07 mSv/h release threshold. Using I-131's physical half-life of 8.02 days (a conservative choice, since biological clearance shortens the effective half-life), the mean life is:

1.44 \times 8.02 d \times 24 h/d \approx 277 h

For a spouse in close, sustained contact — assume an average distance of $d = 1 m$ and an occupancy factor $E = 0.25$ (a common default for a household member):

D = \frac{0.05}{1 ^{2}} \times 0.25 \times 277 \approx 3.5 mSv

This is below the 5 mSv release criterion but above the 1 mSv instruction trigger — so release is permitted, but written ALARA instructions are required, and simple precautions matter. Now apply the instructions: the spouse increases the sleeping distance so the average contact distance rises to $d = 2 m$ :

D = \frac{0.05}{2 ^{2}} \times 0.25 \times 277 \approx 0.87 mSv

Doubling the distance cut the projected dose by a factor of four — from above 1 mSv to below it. That single number is the entire case for distance-based instructions, and it is why "sleep in a separate bed for a few nights" is not folklore but physics. (These are illustrative assumptions; a defensible release uses the patient's measured dose rate, realistic living arrangements, and, where appropriate, effective half-life.)

Why radioiodine dominates

Among therapy radionuclides, I-131 typically produces the largest doses to staff, the public, caregivers, and relatives, because it combines an energetic gamma emission with an 8.02-day half-life and biological pathways (saliva, urine, sweat, breast milk) that create contamination as well as external exposure.⁴ Many other therapy radionuclides — including simple beta emitters such as Y-90 — pose much less external hazard. Lu-177, widely used for neuroendocrine and prostate cancer therapy, has a 6.647-day half-life and lower-energy photon emissions than I-131, so its caregiver doses are generally lower, but the same 10 CFR 35.75 release-and-instruction structure applies.⁴ The exposure-rate constants used to translate activity into dose rate for any given radionuclide are tabulated in standard references.⁶

Clinical Impact

The difference between a well-managed release and a poorly managed one is measured in the doses that real families actually receive. The physics above shows that the dominant controls are distance and time, and that they are enormously effective: a factor-of-two change in distance is a factor-of-four change in dose. Instructions that translate this into concrete household behavior — sleeping arrangements, contact time with children, bathroom hygiene, laundry, travel — are what keep a spouse comfortably under the comforter-and-carer constraint and keep children under the public limit.⁴

The consequences of getting it wrong are not abstract. A young child held close for long periods by a treated parent, or an infant breastfed after radioiodine therapy, can receive doses far above what a knowing adult caregiver would — which is exactly why the framework pulls children out of the caregiver category and into the public-limit category.⁴ A patient who is not told to increase distance, or who returns to a job caring for infants, can deliver dose to third parties that a few sentences of instruction would have prevented.

There is also a program-integrity dimension. Under 10 CFR 35.75, the licensee must maintain a record of the basis for release when instructions were required and, for certain cases, the calculation supporting the decision. A therapy program that cannot show how it concluded that a release met the 5 mSv criterion — what dose rate, what assumptions, what instructions — has a documentation gap that surfaces immediately in an inspection. For the recordkeeping backbone, see our guide to patient release after radiopharmaceutical therapy and, for the nursing-mother pathway specifically, breastfeeding interruption after radiopharmaceuticals.

Practical Optimization Tips

Base the release on the right patient-specific information

Use the measured dose rate at release and realistic living arrangements rather than a generic activity cutoff whenever the situation is non-standard — a patient who lives with a pregnant partner or young children, uses public transport, or shares a small dwelling deserves a patient-specific evaluation.²

Make the written instructions concrete and behavioral

Translate the physics into specific, time-bound actions: maintain distance from others (especially children and pregnant women), sleep separately for a defined period, limit close contact time, practice careful toilet and hand hygiene, launder the patient's items separately, and avoid prolonged travel next to others in the highest-dose-rate period.²⁴

Treat children and pregnant contacts as the public

Design the instructions so that dose to young children, infants, and pregnant household members is held to the public limit, not the caregiver constraint. This usually means the strictest distance and time guidance applies to those interactions.⁴⁵

Address breastfeeding explicitly before release

For any therapy that concentrates in breast milk, confirm breastfeeding status before administration and give explicit interruption or cessation instructions; for radioiodine, breastfeeding must stop.¹⁴

Document the basis for release

Keep the dose-rate measurement, the assumptions, the projected dose to the most exposed individual, and a copy of the instructions provided. If instructions were required because dose could exceed 1 mSv, the record should show it.¹²

Common pitfalls to avoid

Applying the caregiver constraint to a child. Children and infants are held to the public limit, not the "few mSv per episode" constraint.⁴
Releasing on activity alone in a non-standard household. A patient-specific dose evaluation is warranted when living arrangements are unusual.²
Vague instructions. "Be careful around others" is not ALARA guidance; specific distance and time directions are.²
Missing the breastfeeding pathway. Failing to check nursing status before radioiodine can deliver a large thyroid dose to an infant.⁴
No documentation of the release basis. The record must support how the 5 mSv criterion and 1 mSv instruction trigger were evaluated.¹

Regulatory Considerations

Patient release and caregiver-dose management are federal materials-regulation obligations, administered by the NRC or by an Agreement State. The core requirements are in 10 CFR 35.75 (the 5 mSv release criterion and the 1 mSv instruction trigger) and 10 CFR 20.1301 (the 1 mSv public dose limit, and the 20.1301(c) provision for visitors to non-releasable patients).¹⁵ NRC Regulatory Guide 8.39, Revision 1, is the methodology document that most programs follow to demonstrate compliance, and NRC NUREG-1556, Volume 9, sets the licensing expectations for medical-use programs, including patient-release procedures.²⁷

Jurisdiction matters for who enforces these rules. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer equivalent patient-release requirements under their own radiation-control regulations, while Washington, DC and Delaware are regulated directly by the NRC for byproduct material. A therapy program must confirm which authority issues its license and adopt that authority's version of the release rule, but the substantive dose criteria — 5 mSv for release, 1 mSv for instructions, the public dose limit for children and casual visitors — are consistent across the framework.¹⁵

The scientific basis for the dose constraints comes from NCRP Report No. 155, Management of Radionuclide Therapy Patients, and ICRP Publication 94, Release of Patients After Therapy with Unsealed Radionuclides, which together establish the comforter-and-carer constraint of a few mSv per episode and the public-limit treatment of children and non-caregiving visitors.³⁴ Aligning the facility's written procedures and instructions with these documents is what makes the program defensible during inspection.

Frequently Asked Questions (FAQs)

What is the dose limit for releasing a therapy patient home?

Under 10 CFR 35.75, a licensee may release a patient who has received unsealed byproduct material if the total effective dose equivalent to any other individual from exposure to the released patient is not likely to exceed 5 mSv (0.5 rem). This is a per-release criterion focused on the most exposed other person, and it is the same limit reiterated in NRC Regulatory Guide 8.39. The licensee must base the release decision on activity, measured dose rate, or patient-specific calculations.

When must a patient be given written instructions after therapy?

Under 10 CFR 35.75(b), the licensee must provide the released patient, or the patient's parent or guardian, with instructions — including written instructions — on how to keep doses to other people as low as reasonably achievable whenever the total effective dose equivalent to any other individual is likely to exceed 1 mSv (0.1 rem). If a breastfeeding infant could receive more than 1 mSv, the instructions must also address interrupting or discontinuing breastfeeding.

What dose constraint applies to family members and caregivers?

ICRP Publication 94 recommends a source-related dose constraint for optimization of a few mSv per episode for relatives, visitors, and caregivers at home who knowingly and voluntarily help, rather than applying a dose limit to them. However, young children and infants, and visitors not engaged in direct care or comforting, should be treated as members of the public and are subject to the 1 mSv public dose limit.

Are children treated differently from adult caregivers?

Yes. ICRP Publication 94 recommends that young children and infants, as well as visitors who are not providing direct care or comfort, be treated as members of the public and held to the 1 mSv public dose limit rather than the more permissive comforter-and-carer constraint. Written instructions after radioiodine therapy typically emphasize increased distance and reduced time specifically for interactions with children and pregnant household members.

How is dose to a household member estimated?

The dose to another person from a released patient is estimated by modeling the patient as a decaying source, using the measured dose rate at a reference distance, an assumed occupancy factor for the time spent near the patient, the distance during contact, and integration over the effective decay of the radionuclide. NRC Regulatory Guide 8.39 provides the activity thresholds, dose-rate thresholds, and default assumptions used to support the release decision and the instructions.

Can family visit a patient who is kept in the hospital after therapy?

Yes, within limits. Under 10 CFR 20.1301(c), a licensee may permit visitors to a patient who cannot be released under 10 CFR 35.75 to receive a dose greater than 1 mSv if the dose does not exceed 5 mSv and the authorized user has determined before the visit that it is appropriate. This lets a hospitalized therapy patient receive supported visits while keeping visitor dose controlled.

Do these rules apply to Lu-177 therapy as well as I-131?

The 10 CFR 35.75 release framework and the ALARA-instruction obligations apply to any patient released after receiving unsealed byproduct material, including Lu-177 therapies. The specific dose rates, activity thresholds, and precautions differ by radionuclide because photon emissions, half-life, and clearance differ. Iodine-131 typically drives the largest doses to caregivers and the public, so its instructions are usually the most detailed, but Lu-177 releases are managed under the same regulatory structure.

Key Takeaways

5 mSv is the release criterion. Under 10 CFR 35.75, a patient may be released if the TEDE to any other individual is not likely to exceed 5 mSv (0.5 rem).¹
1 mSv triggers instructions. Written ALARA instructions are required when the dose to any other individual is likely to exceed 1 mSv, and the breastfeeding pathway is addressed at the same threshold.¹
Caregivers and children are treated differently. ICRP 94 sets a few-mSv-per-episode constraint for knowing adult caregivers, but children, infants, and casual visitors get the 1 mSv public limit.⁴⁵
Distance and time are the controls. Dose scales as $1/ d^{2}$ and with occupancy, so a factor-of-two increase in distance is a factor-of-four reduction in dose.⁶
Radioiodine dominates. I-131 typically drives the largest caregiver and public doses; Lu-177 and beta emitters are generally lower but follow the same rules.⁴
Document the basis. Keep the dose rate, assumptions, projected dose, and instructions; the record must show how the criteria were met.¹²

Conclusion

Releasing a therapy patient is an act of trust in physics and in people: trust that distance, time, and a decaying source term will keep household doses acceptable, and trust that the patient will follow the instructions that make it so. The radiation safety program's job is to make that trust well-founded — to apply the 5 mSv release criterion honestly, to hand over concrete written instructions whenever dose could exceed 1 mSv, to pull children and infants into the protective public-limit category, and to document the basis for every release.

Done well, caregiver-dose management is nearly invisible: the patient goes home, the family follows a few sensible precautions, and no one receives a dose worth worrying about. Done poorly, it delivers avoidable exposure to the people a patient loves most. The difference is a defensible calculation and a clear set of instructions — exactly the work a radiation safety program exists to do.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and radiopharmaceutical therapy programs build defensible patient-release procedures: dose-rate measurement protocols, patient-specific release calculations, radionuclide-specific written instructions for patients and caregivers, breastfeeding and pregnancy screening workflows, and the recordkeeping that inspections require — delivered by board-certified medical physicists through our radioactive material license support, radiation safety officer consulting, and PET/CT and nuclear medicine physics services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong therapy program does not stop caring about dose when the patient leaves the department. It follows the source home — on paper, in instructions, and in the doses the family never has to think about.

Related Resources

References

U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. ecfr.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39, Revision 1: Release of Patients Administered Radioactive Material. 2020. nrc.gov
National Council on Radiation Protection and Measurements. Management of Radionuclide Therapy Patients. NCRP Report No. 155. Bethesda, MD: NCRP; 2006. ncrponline.org
International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Ann ICRP. 2004;34(2):v-vi, 1-79. doi:10.1016/j.icrp.2004.08.001. doi.org
U.S. Nuclear Regulatory Commission. 10 CFR 20.1301: Dose limits for individual members of the public. ecfr.gov
Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 2012;102(3):271-291. doi:10.1097/HP.0b013e318235153a. doi.org
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
National Nuclear Data Center, Brookhaven National Laboratory. NuDat: Nuclear Structure and Decay Data (I-131 and Lu-177 half-lives). nndc.bnl.gov
Society of Nuclear Medicine and Molecular Imaging. Guidelines for Patients Receiving Radioiodine I-131 Treatment (patient fact sheet). snmmi.org